Find Levofloxacin Hemihydrate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

0

Canada

0

Australia

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 138199-71-0, Levofloxacin hydrate, 6gnt3y5lmf, Nofaxin, Quinsair, Volequin
Molecular Formula
C36H42F2N6O9
Molecular Weight
740.7  g/mol
InChI Key
SUIQUYDRLGGZOL-RCWTXCDDSA-N
FDA UNII
6GNT3Y5LMF

Levofloxacin Hemihydrate
The L-isomer of Ofloxacin.
Levofloxacin is a Quinolone Antimicrobial.
1 2D Structure

Levofloxacin Hemihydrate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid;hydrate
2.1.2 InChI
InChI=1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1
2.1.3 InChI Key
SUIQUYDRLGGZOL-RCWTXCDDSA-N
2.1.4 Canonical SMILES
CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O.CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O.O
2.1.5 Isomeric SMILES
C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O.C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O.O
2.2 Other Identifiers
2.2.1 UNII
6GNT3Y5LMF
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Anhydrous, Levofloxacin

2. Levaquin

3. Levofloxacin

4. Levofloxacin Anhydrous

5. Ofloxacin, (s)-isomer

6. Quixin

2.3.2 Depositor-Supplied Synonyms

1. 138199-71-0

2. Levofloxacin Hydrate

3. 6gnt3y5lmf

4. Nofaxin

5. Quinsair

6. Volequin

7. Levaquin (tn)

8. Ofloxacin, (s)-

9. Rwj-25213

10. (-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid, Hemihydrate

11. 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-hydrate (2:1), (s)-

12. Levofloxacin [usan]

13. Dynaquin

14. Levofloxacin (as Hemihydrate)

15. (s)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid Hemihydrate

16. Unii-6gnt3y5lmf

17. Rwj 25213

18. Tavanic Hydrate

19. Cravit Hydrate

20. Iquix Hydrate

21. Quixin Hydrate

22. Levaquin Hydrate

23. Mfcd07772024

24. Levofloxacin (usp)

25. Quixin (tn)

26. Lvfx

27. Iquix (tn)

28. (s)-(-)-ofloxacine

29. (2s)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic Acid;hydrate

30. Levofloxacin [vandf]

31. Levofloxacin [mart.]

32. (s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid Hydrate (2:1)

33. (s)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid Hydrate(2:1)

34. Levofloxacin Hydrate (jp17)

35. Levofloxacin [usp-rs]

36. Levofloxacin Hemihidrated

37. Schembl1650602

38. Dtxsid60160533

39. Levofloxacin [orange Book]

40. Levofloxacin Hydrate [jan]

41. Levofloxacin [usp Monograph]

42. Akos015896149

43. Ks-1077

44. Levofloxacin [usan:usp:inn:ban:jan]

45. Levofloxacin Hemihydrate [who-dd]

46. 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, Hydrate (2:1), (s)-

47. D00588

48. Levofloxacin Hemihydrate [ep Monograph]

49. Ofloxacin S-(-)-form Hemihydrate [mi]

50. 199l710

51. A886273

52. Q47495791

53. Levofloxacin, United States Pharmacopeia (usp) Reference Standard

54. 3 Inverted Exclamation Mark ,5 Inverted Exclamation Mark -difluoro-4-propylbiphenyl

55. Levofloxacin Hemihydrate, Pharmaceutical Secondary Standard; Certified Reference Material

56. (s)-(-)-ofloxacine; Levofloxacine; (-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid Hydrochloride; Levofloxacin Hemihydrate;(s)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid Hemihydrate

57. (s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid Hemihydrate

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 740.7 g/mol
Molecular Formula C36H42F2N6O9
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count17
Rotatable Bond Count4
Exact Mass740.29813326 g/mol
Monoisotopic Mass740.29813326 g/mol
Topological Polar Surface Area148 Ų
Heavy Atom Count53
Formal Charge0
Complexity634
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Drug and Medication Information
4.1 Drug Indication

Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.


Treatment of cystic fibrosis


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)


Anti-Infective Agents, Urinary

Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)


Topoisomerase II Inhibitors

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)


Cytochrome P-450 CYP1A2 Inhibitors

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inhibitors.)


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
LEVOFLOXACIN
5.2.2 FDA UNII
6GNT3Y5LMF
5.2.3 Pharmacological Classes
Chemical Structure [CS] - Quinolones
5.3 ATC Code

J01MA12


Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Looking for 138199-71-0 / Levofloxacin Hemihydrate API manufacturers, exporters & distributors?

Levofloxacin Hemihydrate manufacturers, exporters & distributors 1

10

PharmaCompass offers a list of Levofloxacin Hemihydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Levofloxacin Hemihydrate manufacturer or Levofloxacin Hemihydrate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Levofloxacin Hemihydrate manufacturer or Levofloxacin Hemihydrate supplier.

API | Excipient name

Levofloxacin Hemihydrate

Synonyms

138199-71-0, Levofloxacin hydrate, 6gnt3y5lmf, Nofaxin, Quinsair, Volequin

Cas Number

138199-71-0

Unique Ingredient Identifier (UNII)

6GNT3Y5LMF

About Levofloxacin Hemihydrate

The L-isomer of Ofloxacin.

Dynaquin Manufacturers

A Dynaquin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dynaquin, including repackagers and relabelers. The FDA regulates Dynaquin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dynaquin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Dynaquin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Dynaquin Suppliers

A Dynaquin supplier is an individual or a company that provides Dynaquin active pharmaceutical ingredient (API) or Dynaquin finished formulations upon request. The Dynaquin suppliers may include Dynaquin API manufacturers, exporters, distributors and traders.

click here to find a list of Dynaquin suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Dynaquin USDMF

A Dynaquin DMF (Drug Master File) is a document detailing the whole manufacturing process of Dynaquin active pharmaceutical ingredient (API) in detail. Different forms of Dynaquin DMFs exist exist since differing nations have different regulations, such as Dynaquin USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Dynaquin DMF submitted to regulatory agencies in the US is known as a USDMF. Dynaquin USDMF includes data on Dynaquin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dynaquin USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Dynaquin suppliers with USDMF on PharmaCompass.

Dynaquin JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Dynaquin Drug Master File in Japan (Dynaquin JDMF) empowers Dynaquin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Dynaquin JDMF during the approval evaluation for pharmaceutical products. At the time of Dynaquin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Dynaquin suppliers with JDMF on PharmaCompass.

Dynaquin KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Dynaquin Drug Master File in Korea (Dynaquin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Dynaquin. The MFDS reviews the Dynaquin KDMF as part of the drug registration process and uses the information provided in the Dynaquin KDMF to evaluate the safety and efficacy of the drug.

After submitting a Dynaquin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Dynaquin API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Dynaquin suppliers with KDMF on PharmaCompass.

Dynaquin CEP

A Dynaquin CEP of the European Pharmacopoeia monograph is often referred to as a Dynaquin Certificate of Suitability (COS). The purpose of a Dynaquin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dynaquin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dynaquin to their clients by showing that a Dynaquin CEP has been issued for it. The manufacturer submits a Dynaquin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dynaquin CEP holder for the record. Additionally, the data presented in the Dynaquin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dynaquin DMF.

A Dynaquin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dynaquin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Dynaquin suppliers with CEP (COS) on PharmaCompass.

Dynaquin WC

A Dynaquin written confirmation (Dynaquin WC) is an official document issued by a regulatory agency to a Dynaquin manufacturer, verifying that the manufacturing facility of a Dynaquin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Dynaquin APIs or Dynaquin finished pharmaceutical products to another nation, regulatory agencies frequently require a Dynaquin WC (written confirmation) as part of the regulatory process.

click here to find a list of Dynaquin suppliers with Written Confirmation (WC) on PharmaCompass.

Dynaquin GMP

Dynaquin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Dynaquin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Dynaquin GMP manufacturer or Dynaquin GMP API supplier for your needs.

Dynaquin CoA

A Dynaquin CoA (Certificate of Analysis) is a formal document that attests to Dynaquin's compliance with Dynaquin specifications and serves as a tool for batch-level quality control.

Dynaquin CoA mostly includes findings from lab analyses of a specific batch. For each Dynaquin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Dynaquin may be tested according to a variety of international standards, such as European Pharmacopoeia (Dynaquin EP), Dynaquin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dynaquin USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty